Residential College | false |
Status | 已發表Published |
Biomimetic Redox-Responsive Mesoporous Organosilica Nanoparticles Enhance Cisplatin-Based Chemotherapy | |
Chen, Fangman1,2; Zhang, Fan2; Wang, Yanbin3; Peng, Jiahui1,2; Cao, Lei1,2; Mei, Qian2; Ge, Mingfeng2; Li, Li2; Chen, Meiwan4; Dong, Wen Fei1,2; Chang, Zhimin2 | |
2022-03-16 | |
Source Publication | Frontiers in Bioengineering and Biotechnology |
ISSN | 2296-4185 |
Volume | 10Pages:860949 |
Abstract | Cisplatin-based chemotherapy is dominated in several cancers; however, insufficient therapeutic outcomes and systemic toxicity hamper their clinical applications. Controlled release of cisplatin and reducing inactivation remains an urgent challenge to overcome. Herein, diselenide-bridged mesoporous organosilica nanoparticles (MON) coated with biomimetic cancer cell membrane were tailored for coordination responsive controlled cisplatin delivery and GSH depletion to strengthen Pt-based chemotherapy. Cisplatin-loaded MON (MON-Pt) showed high loading capacity due to robust coordination between selenium and platinum atoms and preventing premature leakage in normal tissue. MON-Pt exhibited a controlled release of activated cisplatin in response to the redox tumor microenvironment. Meanwhile, MON-Pt containing redox-responsive diselenide bonds could efficiently scavenge intracellular inactivation agents, such as GSH, to enhance Pt-based chemotherapy. 4T1 breast cancer cell membranes cloaked MON-Pt (MON-Pt@CM) performed efficient anticancer performance and low in vivo system toxicity due to long blood circulation time and high tumor accumulation benefiting from the tumor targeting and immune-invasion properties of the homologic cancer cell membrane. These results suggest a biomimetic nanocarrier to control release and reduce the inactivation of cisplatin for efficient and safe Pt-based chemotherapy by responding and regulating the tumor microenvironment. |
Keyword | Biomimetic Nanocarrier Cisplatin Degradation Glutathione Depletion Mesoporous Silica Nanoparticles |
DOI | 10.3389/fbioe.2022.860949 |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Biotechnology & Applied Microbiology ; Science & Technology - Other Topics |
WOS Subject | Biotechnology & Applied Microbiologymultidisciplinary Sciences |
WOS ID | WOS:000777706000001 |
Publisher | FRONTIERS MEDIA SAAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND |
Scopus ID | 2-s2.0-85127821923 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Institute of Chinese Medical Sciences |
Corresponding Author | Dong, Wen Fei; Chang, Zhimin |
Affiliation | 1.School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China 2.CAS Key Laboratory of Bio Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences, Suzhou, China 3.Nephrology Department of the Fourth Affiliated Hospital of XinJiang Medical University, Macao 4.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao |
Recommended Citation GB/T 7714 | Chen, Fangman,Zhang, Fan,Wang, Yanbin,et al. Biomimetic Redox-Responsive Mesoporous Organosilica Nanoparticles Enhance Cisplatin-Based Chemotherapy[J]. Frontiers in Bioengineering and Biotechnology, 2022, 10, 860949. |
APA | Chen, Fangman., Zhang, Fan., Wang, Yanbin., Peng, Jiahui., Cao, Lei., Mei, Qian., Ge, Mingfeng., Li, Li., Chen, Meiwan., Dong, Wen Fei., & Chang, Zhimin (2022). Biomimetic Redox-Responsive Mesoporous Organosilica Nanoparticles Enhance Cisplatin-Based Chemotherapy. Frontiers in Bioengineering and Biotechnology, 10, 860949. |
MLA | Chen, Fangman,et al."Biomimetic Redox-Responsive Mesoporous Organosilica Nanoparticles Enhance Cisplatin-Based Chemotherapy".Frontiers in Bioengineering and Biotechnology 10(2022):860949. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment